← ANALYST RATINGS · TIPRANKS
Kymera Therapeutics (KYMR): analyst forecast and price target
Analyst consensus
Strong Buy14 Buy2 Hold0 Sell
Ratings of 16 analysts in the last 3 months12-month forecast
Based on 16 price targets given in the last 3 months, the average target is $142, the highest $180, the lowest $112. The average is +35.0% from the last price of $105.
Analyst ratings 27
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| Geoff Meacham★★★★★★★★★★#407 · hits 60% · avg +15.3% | Citi | $150 | Buy | +43.2% | Reiterated | 15.10.26on TipRanks 07:45 | +0.9%next day −2.0% | ↗ |
| Derek Archila★★★★★★★★★★#252 · hits 58% · avg +22.7% | Wells Fargo | $151 | Buy | +44.1% | Reiterated | 15.10.26on TipRanks 07:36 | +0.9%next day −2.0% | ↗ |
| Name not given | — | $140 | Buy | +33.6% | Initiated | 08.10.26on TipRanks Oct 11 09:55 | +1.3%next day +2.2% · 5 days −0.8% | ↗ |
| Geoff Meacham★★★★★★★★★★#407 · hits 60% · avg +15.3% | Citi | $135 → $150+11.1% | Buy | +43.2% | Reiterated | 05.10.26on TipRanks 05:31 | +1.6%next day −4.1% · 5 days +1.6% | ↗ |
| Brian Cheng★★★★★★★★★★#1122 · hits 55% · avg +14.0% | J.P. Morgan | $140 | Buy | +33.6% | Reiterated | 28.09.26on TipRanks 07:40 | +0.8%next day −1.1% · 5 days −3.1% | ↗ |
| Biren Amin★★★★★★★★★★#1671 · hits 46% · avg +7.6% | Piper Sandler | $140 | Buy | +33.6% | Reiterated | 23.09.26on TipRanks 08:15 | −4.7%next day +0.4% · 5 days −2.5% | ↗ |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $125 → $129+3.2% | Hold | +23.1% | Reiterated | 23.09.26on TipRanks 06:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $125 → $130+4.0% | Hold | +24.1% | Reiterated | 23.09.26on TipRanks 06:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $123 → $128+4.1% | Hold | +22.2% | Reiterated | 23.09.26on TipRanks 06:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $119 → $123+3.4% | Hold | +17.4% | Reiterated | 23.09.26on TipRanks 06:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $124 → $129+4.0% | Hold | +23.1% | Reiterated | 23.09.26on TipRanks 06:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $126 → $131+4.0% | Hold | +25.0% | Reiterated | 23.09.26on TipRanks 06:05 | — | |
| Alex Thompson CFA★★★★★★★★★★#60 · hits 73% · avg +50.6% | Stifel Nicolaus | $132 → $152+15.2% | Buy | +45.1% | Reiterated | 22.09.26on TipRanks 06:30 | +3.7%next day −4.7% · 5 days −8.3% | ↗ |
| Tazeen Ahmad★★★★★★★★★★#1537 · hits 60% · avg +5.8% | Bank of America Securities | $123 → $144+17.1% | Buy | +37.4% | Reiterated | 14.09.26on TipRanks 06:10 | +0.2%next day −0.8% · 5 days +0.7% | ↗ |
| Andy Chen★★★★★★★★★★#959 · hits 67% · avg +28.8% | Wolfe Research | $180 | Buy | +71.8% | Upgrade | 10.09.26on TipRanks 05:45 | +2.0%next day −2.6% · 5 days +0.6% | ↗ |
| Brian Abrahams★★★★★★★★★★#481 · hits 57% · avg +15.1% | RBC Capital | $112 | Hold | +6.9% | Reiterated | 02.09.26on TipRanks 07:35 | −0.8%next day −2.2% · 5 days −0.4% | ↗ |
| Bradley Canino★★★★★★★★★★#1614 · hits 46% · avg +10.8% | Guggenheim | $135 → $170+25.9% | Buy | +62.2% | Assigned | 30.08.26on TipRanks Aug 31 07:25 | +0.9%next day +0.9% · 5 days −1.8% | ↗ |
| Derek Archila★★★★★★★★★★#252 · hits 58% · avg +22.7% | Wells Fargo | $116 → $151+30.2% | Buy | +44.1% | Assigned | 27.08.26on TipRanks 07:15 | −4.9%next day −1.5% · 5 days −2.7% | ↗ |
| Judah Frommer★★★★★★★★★★#2495 · hits 56% · avg +5.3% | Morgan Stanley | $119 → $135+13.4% | Buy | +28.8% | Assigned | 06.08.26on TipRanks 07:55 | +1.0%next day +0.4% · 5 days +6.3% | ↗ |
| Edward Nash★★★★★★★★★★#204 · hits 52% · avg +29.5% | Canaccord Genuity | $129 | Buy | +23.1% | Reiterated | 06.08.26on TipRanks 07:06 | +1.0%next day +0.4% · 5 days +6.3% | ↗ |
| Andrew Fein★★★★★★★★★★#267 · hits 52% · avg +23.7% | H.C. Wainwright | $134 | Buy | +27.9% | Reiterated | 06.08.26on TipRanks 06:35 | +1.0%next day +0.4% · 5 days +6.3% | ↗ |
| Geoff Meacham★★★★★★★★★★#407 · hits 60% · avg +15.3% | Citi | $120 → $135+12.5% | Buy | +28.8% | Reiterated | 06.08.26on TipRanks 06:05 | +1.0%next day +0.4% · 5 days +6.3% | ↗ |
| Eliana Merle★★★★★★★★★★#4163 · hits 45% · avg +3.0% | Barclays | $133 → $139+4.5% | Buy | +32.7% | Reiterated | 06.08.26on TipRanks 04:16 | +1.0%next day +0.4% · 5 days +6.3% | ↗ |
| David Dai★★★★★★★★★★#2876 · hits 59% · avg +9.3% | UBS | $128 | Buy | +22.2% | Reiterated | 05.08.26on TipRanks Aug 6 06:50 | +1.2%next day +1.0% · 5 days +7.8% | ↗ |
| David Hoang★★★★★★★★★★#485 · hits 67% · avg +34.8% | Deutsche Bank | $120 | Hold | +14.5% | Initiated | 29.07.26on TipRanks Jul 30 05:17 | +0.7%next day 0.0% · 5 days −5.3% | ↗ |
| Srikripa Devarakonda★★★★★★★★★★#200 · hits 62% · avg +26.3% | Truist Financial | $116 → $136+17.2% | Buy | +29.8% | Assigned | 29.06.26on TipRanks 07:44 | −0.5%next day +4.1% · 5 days +8.2% | ↗ |
| Mayank Mamtani★★★★★★★★★★#2653 · hits 38% · avg +5.8% | B. Riley Securities | $117 → $155+32.5% | Buy | +47.9% | Assigned | 29.06.26on TipRanks Jun 26 09:05 | −6.4%next day −0.5% · 5 days +3.1% | ↗ |
| Jeet Mukherjee★★★★★★★★★★#655 · hits 63% · avg +26.2% | BTIG | $134 | Buy | +27.9% | Reiterated | 25.06.26on TipRanks Jun 26 06:15 | +16.5%next day −6.4% · 5 days −4.0% | ↗ |
| Marc Frahm★★★★★★★★★★#223 · hits 56% · avg +25.8% | TD Cowen | — | Buy | — | Reiterated | 05.05.26on TipRanks May 6 04:05 | −1.9%next day +2.9% · 5 days −1.0% | ↗ |
| Faisal Khurshid★★★★★★★★★★#51 · hits 66% · avg +74.6% | Jefferies | $110 | Buy | +5.0% | Initiated | 15.03.26on TipRanks Mar 16 09:30 | −0.3%next day +1.8% · 5 days −1.5% | ↗ |
| Sudan Loganathan★★★★★★★★★★#1955 · hits 65% · avg +22.0% | Stephens | $95.00 → $100+5.3% | Buy | −4.6% | Reiterated | 02.03.26on TipRanks 07:30 | −1.4%next day −3.3% · 5 days −4.4% | ↗ |
| Jeff Jones★★★★★★★★★★#749 · hits 46% · avg +20.3% | Oppenheimer | $120 | Buy | +14.5% | Reiterated | 27.02.26on TipRanks 08:40 | −3.4%next day −1.4% · 5 days −6.6% | ↗ |
| Unknown Analyst | Mizuho Securities | $59.83 → $81.00+35.4% | Buy | −22.7% | Initiated | 21.10.25on TipRanks Oct 20 16:20 | −3.6%next day −3.8% · 5 days +3.9% | ↗ |
| No ratings for this filter. | ||||||||
Every rating the collector has kept for the last 12 months, including the earlier ones of the same analyst. Latest of each analyst
Best analysts covering Kymera Therapeutics
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $141 at a price of $112 (+25.8%); now: $142 at $105 (+35.0%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 5 | 3 | 1 | 1 | 1 |
| Buy | 16 | 22 | 22 | 31 | 22 | 23 |
| Hold | 0 | 0 | 2 | 3 | 5 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 29.10.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-1.27 (from $-1.47 to $-1.04). Last quarter: $-0.62.
Sales
Next quarter’s sales estimate — $3M (from $-1M to $20M). Last quarter: $65M.
Best top-analyst consensus in the sector · Healthcare
About Kymera Therapeutics
- CEO: Nello Mainolfi
- Employees: 273
- 500 North Beacon Street, Watertown, MA, 02472, US
- www.kymeratx.com
Kymera Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and developing pioneering small molecule therapeutics. These treatments operate by harnessing the body's inherent protein degradation system to selectively eliminate disease-causing proteins. The company's pipeline features several programs, including the IRAK4 program, currently in Phase I clinical trials, which targets various immunology-inflammation disorders such as hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, generalized pustular psoriasis, and rheumatoid arthritis. Additionally, Kymera is advancing its IRAKIMiD program, designed to address MYD88-mutated diffuse large B cell lymphoma. Other key programs include the STAT3 program, focused on hematological malignancies, solid tumors, autoimmune diseases, and fibrosis, as well as the MDM2 program, which is also aimed at hematological malignancies and solid tumors. The company was founded in 2015 and maintains its headquarters in Watertown, Massachusetts.
Data from the stock’s TipRanks forecast page, read 25 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗